SUMMARY Twenty one patients with severe systemic lupus erythematosus (SLE) were treated with three daily infusions of either 100 mg or 1 g of methylprednisolone on a randomised double blind basis. Nine patients with unsatisfactory outcome subsequently received the alternative therapy. Patients were rated for improvement on a four point scale using individualised criteria. On three occasions patients improved to 'ideal', on 12 there was 'useful' improvement, on 11 the patient remained static, and on four occasions there was deterioration. There was no significant difference between the clinical states after the two doses. The results suggest that any additional benefit of 1 g of methylprednisolone over 100 mg by repeated infusion in the treatment of active SLE is probably not enough to justify the potential hazards and cost involved.
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The use of repeated daily infusions of 1 The mean daily dosage of prednisolone was 7-7 mg/day.
group Methylprednisolone was made up in 500 ml of normal saline or dextrose saline and infused over 
Results
Unwanted effects attributable to methylprednisolone were few. No gastrointestinal bleeding occurred. (Massive bleeding had been experienced on one occasion previously using 1 g doses in a patient with rheumatoid arthritis with a previous history of duodenal ulceration.) No osteonecrosis occurred. Blood pressure rose temporarily in some patients but did not require treatment other than bed rest. Headache, mood swings, and other non-specific symptoms did not cause significant distress, and no patient refused repeated treatment on the basis of unwanted effects. Plasma urea levels rose in many cases, as did creatinine levels in a smaller proportion, but these returned to pretreatment levels within two weeks. Raised serum glucose levels were transient and not associated with symptoms. Of the 21 treatment courses given at the initial dose, three were associated with ideal improvement, eight with useful improvement, six with no change, and four with significant deterioration. The details of these outcomes are given in Table 3 . The outcomes associated with 1 g were slightly worse than those with 100 mg, so there was no question of a statistically significant benefit from the higher dose.
After the alternative dosage four patients showed useful improvement (two at each dose) and five were static (three at 1 g and two at 100 mg).
When improvement occurred there was, as a rule, rapid and dramatic relief of symptoms within a few days, as might be expected from high dose steroid.
Discussion
The results of this study suggest that although about half of patients with severe episodes of SLE treated with infusions of methylprednisolone may be expected to show improvement at three months, three doses of 1 g do not appear to have any advantage over three of 100 mg. The study fails to support the idea of a specific action of very high dose steroid in the treatment of severe episodes of SLE.
The trial was designed purely to answer a question about management of end organ problems in SLE and not to provide information about the disease process. In this context the over-riding aim was to extract the most powerful statistical information possible from heterogeneous data. Ideally, one would like to study large homogeneous groups with similar end organ problems, but it is unlikely that this can be achieved.
In trying to answer a question of outcome, the power of the statistical analysis is reduced in proportion to the number of analyses made which relate to the question. When dealing with very small numbers the only option is to use one outcome measure. A point scoring system using a range of clinical data which provided a sensitive reflection of each patient's problems would have to be based on an unmanageable set of rules involving many inter-related contingencies, involving time relationships and subtle grades of severity.
As an alternative we used a system of individualised criteria. This is equally valid statistically and can be much more closely tailored to events of importance to Even with the use of individualised outcome criteria the power of the statistical analysis is weak because of small numbers. The study may not have detected a modest difference in effect between the two dosages, demonstrating the almost insuperable problems of studying uncommon heterogeneous disease. Nevertheless, we consider that individualisation of outcome criteria goes part of the way to solving this problem and can be a very valuable technique. 
